http://www.OncoLyticVirus.org
Table III- OVs targeting defective p53 tumor suppressor pathway.

Virus (Company, if known)

Mutated viral gene

Cellular target

Effect

References

Adenovirus ONYX-015  (Onyx Pharmaceuticals)

E1B-55Kd

p53

Viral replication restricted to p53-defective mutants

(20)

Adenovirus 01/PEME (Canji)

1)       p53 promoter driving expression of E2F antagonist

2)       E1A-CR1 p300 binding-domain

3)       E3 deletion

4)       Extra Major Late Promoter driving expression of E3-11.6 Kd

p53, p300.

Expression of E2 and subsequent viral genes dependent on loss of p53 function; wild-type p53 function enhanced by p300 coactivation; increased adenoviral release and cell death by  adenoviral death protein (21)

(22)

AAV

AAV unusual DNA structure is precipitating factor

p53/ p21

Lack of G2/M arrest in p53-defective cells, infected with AAV, causes cell death

(23)


Disclaimer About Medical Information: The information and reference materials contained herein is intended solely for the information of the reader. It should not be used for treatment purposes, but rather for discussion with the patient's own physician.
[Divider]
electronswebs
All Rights Reserved. Copyright © 2004 E.A. Chiooca, MD
Last modified: Thursday, April 20, 2006 5:04 PM .
Site Issues Contact: Webmaster Email